Filtered By:
Specialty: Hematology
Therapy: Stem Cell Therapy

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 242 results found since Jan 2013.

Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research

Low Rates of Cerebral Infarction after Hematopoietic Stem Cell Transplantation in Patients with Sickle Cell Disease at High Risk for Stroke
(CNS)
Source: Biology of Blood and Marrow Transplantation - September 13, 2021 Category: Hematology Authors: Jessica L. Carpenter, Robert S. Nickel, Jennifer Webb, Zarir Khademian, Barbara Speller-Brown, Suvankar Majumdar, Deepika S. Darbari, Andrew Campbell, Anqing Zhang, Allistair Abraham Source Type: research

Allogenic Hematopoietic Stem Cell Transplantation in Sickle Cell Disease
Sickle cell disease (SCD) is one of the most common monogenic disorders worldwide and affects approximately 100,000 people in the United States alone. SCD can cause numerous complications, including anemia, pain, stroke, and organ failure, which can lead to death. Although there are a few disease-modifying treatments available to patients with SCD, the only current curative option is a hematopoietic stem cell transplant (HSCT). In this review, we will discuss the different approaches to allogeneic HSCT in the treatment of SCD and the outcomes of these approaches.
Source: Transfusion and Apheresis Science - January 10, 2021 Category: Hematology Authors: Dana K. Furstenau, John F. Tisdale Source Type: research

Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119)
After solid organ or hematopoietic stem cell transplantation (HSCT), the risk of arterial or venous thromboembolism (VTE) is high (1 –7). Oral anticoagulation represents the mainstay for stroke prevention in atrial fibrillation (SPAF) and VTE treatment. The pharmacodynamic and pharmacokinetic profiles of vitamin k antagonists (VKA) represent a challenge especially in the setting of transplantation, also due to the high risk of bleeding (8) and due to complex co-medications of transplant recipients.
Source: Thrombosis Research - April 23, 2020 Category: Hematology Authors: Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, Luise Tittl, Katja Sockel, Jan Moritz Middecke, Martin Bornh äuser Tags: Letter to the Editors-in-Chief Source Type: research

Environmental Influences on Clonal Hematopoiesis
Clonal hematopoiesis (CH) is a condition in which one or a few individual hematopoietic stem cells (HSCs) contribute disproportionately to peripheral blood production [1 –3]. Not only are individuals with CH at significantly greater risk of developing hematologic malignancies compared to their non-CH counterparts, but importantly they have greater all-cause mortality largely from heart disease and stroke [2, 4]. The prevalence of clonal hematopoiesis increases wit h age and is thought to occur at some level in virtually all people [5], such that around 20% of individuals above the age of 70 have at least one HSC clone th...
Source: Experimental Hematology - December 28, 2019 Category: Hematology Authors: Katherine Y. King, Yun Huang, Daisuke Nakada, Margaret A. Goodell Source Type: research

Human stem cells transplanted into the rat stroke brain migrate to spleen via lymphatic and inflammation pathways.
This study is the first to demonstrate brain-to-periphery migration of stem cells, advancing the novel concept of harnessing the lymphatic system in mobilizing stem cells to sequester peripheral inflammation as a brain repair strategy. PMID: 30514806 [PubMed - as supplied by publisher]
Source: Haematologica - December 4, 2018 Category: Hematology Authors: Xu K, Lee JY, Kaneko Y, Tuazon JP, Vale F, van Loveren H, Borlongan CV Tags: Haematologica Source Type: research

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy
ConclusionsIn this pilot study of 50 patients, low-dose apixaban was safe and well tolerated as thromboprophylaxis for patients with MM receiving IMiDs. No patients experienced VTE, major hemorrhage, stroke, or MI. Further randomized studies are needed to validate apixaban as a standard primary prevention anti-thrombotic strategy for patients with MM receiving IMiDs.DisclosuresMoslehi: Bristol-Myers Squibb: Consultancy, Research Funding. Jagasia: Incyte Corporation: Membership on an entity's Board of Directors or advisory committees.
Source: Blood - November 21, 2018 Category: Hematology Authors: Cornell, R. F., Goldhaber, S. Z., Engelhardt, B. G., Moslehi, J., Jagasia, M., Patton, D., Harrell, S. L., Hall, R. L., Wyatt, H., Piazza, G. Tags: 332. Antithrombotic Therapy: Poster I Source Type: research

Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia -- Final Results of a Prospective Phase 2 Study
CONCLUSION:Pomalidomide with prednisone is safe therapy with good anti-anemia activity in patients with MF. It could lead to transfusion independence in one third of patients for a median duration of about 30 months. ClinicalTrials.gov Identifier: NCT00946270.Table 1.DisclosuresDaver: Alexion: Consultancy; ImmunoGen: Consultancy; Pfizer: Research Funding; Karyopharm: Research Funding; Otsuka: Consultancy; Novartis: Consultancy; ARIAD: Research Funding; Incyte: Consultancy; Pfizer: Consultancy; BMS: Research Funding; Sunesis: Research Funding; Daiichi-Sankyo: Research Funding; Sunesis: Consultancy; Kiromic: Research Funding...
Source: Blood - November 21, 2018 Category: Hematology Authors: Masarova, L., Daver, N. G., Kadia, T. M., Pemmaraju, N., Jabbour, E. J., Zhou, L., Pierce, S. A., Cortes, J. E., Kantarjian, H. M., Verstovsek, S. Tags: 634. Myeloproliferative Syndromes: Clinical: Poster I Source Type: research

Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study
Backgroundβ-globin gene transfer has the potential for substantial clinical benefit in patients with sickle cell disease (SCD). LentiGlobin Drug Product (DP) contains autologous CD34+ hematopoietic stem cells (HSCs) transduced with the BB305 lentiviral vector (LVV), encoding β-globin with an anti-sickling substitution (T87Q). The safety and efficacy of LentiGlobin gene therapy is being evaluated in the ongoing Phase 1 HGB-206 study (NCT02140554). Results in the initial 7 patients treated with LentiGlobin DP from steady state bone marrow harvested (BMH) HSCs using original DP manufacturing process (Group A) demons...
Source: Blood - November 21, 2018 Category: Hematology Authors: Tisdale, J. F., Kanter, J., Mapara, M. Y., Kwiatkowski, J. L., Krishnamurti, L., Schmidt, M., Miller, A. L., Pierciey, F. J., Shi, W., Ribeil, J.-A., Asmal, M., Thompson, A. A., Walters, M. C. Tags: 801. Gene Therapy and Transfer: Gene Therapy for Blood Cell Disorders Source Type: research

Medical Conditions Among Survivors of Adolescent and Young Adult Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Conclusion: This study found that sociodemographic factors were associated with the risk of developing medical conditions in AYA NHL, ALL and AML survivors. As expected, the risk of medical conditions varied by cancer type and treatment, with those undergoing SCT having a higher risk of medical conditions regardless of cancer type. NHL and ALL survivors who were uninsured or publicly insured were at a consistently higher risk of developing medical conditions, as were Hispanic ALL survivors and Black AML survivors. Our findings highlight the higher burden of medical conditions in subgroups of cancer survivors that may relat...
Source: Blood - November 21, 2018 Category: Hematology Authors: Keegan, T. H. M., Muffly, L. S., Li, Q., Alvarez, E., Brunson, A. M., Malogolowkin, M., Wun, T. Tags: 904. Outcomes Research-Malignant Conditions: Real World Outcomes Source Type: research

Outcomes in Children with Severe Vasculopathy from Sickle Cell Anemia after Treatment with Chronic Transfusion, Surgical Revascularization and/or Allogenic Hematopoetic Stem Cell Transplantation
Conclusions: The risk for cerebral infarction and/or vasculopathy progression after initiation of treatment with either chronic transfusion, HSCT or EDAS is still a major concern. Our data suggest HSCT and surgical revascularization with chronic transfusion provide the greatest benefit in reducing stroke risk and HSCT reduces risk for progression of a severe vasculopathy. Additional, large population studies are needed to clarify the risk.DisclosuresMajumdar: NIMHD: Research Funding. Campbell: Functional Fluitics: Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Membership on ...
Source: Blood - November 21, 2018 Category: Hematology Authors: Johnson, C. W., Majumdar, S., Campbell, A. D., Magge, S., Darbari, D. S., Webb, J., Diab, Y. A., Nickel, R. S., Speller-Brown, B., Carpenter, J., Abraham, A. Tags: 114. Hemoglobinopathies, Excluding Thalassemia-Clinical: Poster I Source Type: research